Laurindo Lucas Fornari, Laurindo Lívia Fornari, Rodrigues Victória Dogani, Catharin Virgínia Maria Cavallari Strozze, Simili Otávio Augusto Garcia, Barboza Gabriella Oliveira, Catharin Vitor Cavallari Strozze, Sloan Kátia Portero, Barbalho Sandra Maria
Department of Biochemistry and Pharmacology, School of Medicine, Faculdade de Medicina de Marília (FAMEMA), Marília 17519-030, São Paulo, Brazil.
Department of Administration, Associate Degree in Hospital Management, Universidade de Marília (UNIMAR), Marília 17525-902, São Paulo, Brazil.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):165-177. doi: 10.1007/s00210-024-03362-7. Epub 2024 Aug 13.
Type 2 diabetes mellitus (T2DM) is a widespread chronic disease characterized by persistent hyperglycemia, leading to severe complications such as diabetic cardiomyopathy and nephropathy, significantly affecting patient health and quality of life. The complex mechanisms underlying these complications include chronic inflammation, oxidative stress, and metabolic dysregulation. Diabetic cardiomyopathy, marked by structural and functional heart abnormalities, and diabetic nephropathy, characterized by progressive kidney damage, are major contributors to the increased morbidity and mortality associated with T2DM. AdipoRon, a synthetic adiponectin receptor agonist, has shown potential in preclinical studies for mimicking the beneficial effects of endogenous adiponectin, reducing inflammation and oxidative stress, and improving lipid metabolism and mitochondrial function. This systematic review evaluates the therapeutic potential of AdipoRon, focusing on its impact on diabetic cardiomyopathy and nephropathy. Through a comprehensive literature search and analysis, we highlight AdipoRon's role in ameliorating cardiovascular and renal complications in various animal models and cellular systems. The findings underscore the urgent need for translational clinical studies to validate AdipoRon's efficacy and safety in human populations, aiming to advance this promising therapeutic approach from experimental models to clinical application, potentially offering new hope for improved management of diabetic complications.
2型糖尿病（T2DM）是一种广泛存在的慢性疾病，其特征为持续性高血糖，可导致糖尿病性心肌病和肾病等严重并发症，显著影响患者的健康和生活质量。这些并发症背后的复杂机制包括慢性炎症、氧化应激和代谢失调。以心脏结构和功能异常为特征的糖尿病性心肌病以及以进行性肾脏损害为特征的糖尿病肾病，是导致T2DM相关发病率和死亡率增加的主要因素。AdipoRon是一种合成的脂联素受体激动剂，在临床前研究中已显示出模拟内源性脂联素的有益作用、减轻炎症和氧化应激以及改善脂质代谢和线粒体功能的潜力。本系统评价评估了AdipoRon的治疗潜力，重点关注其对糖尿病性心肌病和肾病的影响。通过全面的文献检索和分析，我们强调了AdipoRon在改善各种动物模型和细胞系统中心血管和肾脏并发症方面的作用。研究结果强调迫切需要开展转化临床研究，以验证AdipoRon在人类中的疗效和安全性，旨在将这种有前景的治疗方法从实验模型推进到临床应用，有望为改善糖尿病并发症的管理带来新的希望。
